Your friend lost fifteen pounds on a prescription GLP-1 shot and now scrolls peptide forums for a “backup fat burner.” Someone posts that PT-141, the same melanocortin drug sold as Vyleesi for low desire, also “melts appetite” in weight studies. She forwards the thread and asks whether she should chase a research vial for the scale.
There are short phase 1 weight studies of prescription bremelanotide. They are not a license for a catalog powder, and they are not a substitute for proven obesity care.
What the phase 1 weight studies measured
Spana, Jordan, and Fischkoff published pooled results from two randomized, double-blind, placebo-controlled phase 1 trials in Diabetes, Obesity and Metabolism in 2022. Both enrolled premenopausal women with obesity. One study compared subcutaneous bremelanotide with placebo over about two weeks. The other used a crossover design with multi-day treatment periods that compared different bremelanotide schedules with placebo.
In the longer study, women on bremelanotide lost about 1.3 kilograms more than placebo over roughly sixteen days, and average calorie intake fell by about four hundred calories relative to placebo. In the crossover study, the schedule that used bremelanotide twice in a day produced a larger short-term weight drop than placebo; a lighter schedule did not clearly separate from placebo. Nausea was common on active drug.
These were short, tightly supervised phase 1 experiments run by the company that developed bremelanotide. They tested appetite and early weight change, not long-term obesity treatment, heart outcomes, or diabetes remission.
How that differs from the approved label and from research vials
In the United States, bremelanotide is approved as Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women. The label is not an obesity indication. Everyday Brief has already covered the Vyleesi evidence file, nausea and blood-pressure tradeoffs, and separate studies of PT-141 in men with erectile dysfunction. Weight is a third clinical question.
A research-catalog listing labeled PT-141 is not the same product, manufacturing standard, or indication as prescription Vyleesi. Phase 1 company trials do not transfer to an unverified vial. NIDDK and MedlinePlus describe obesity care around eating patterns, activity, behavioral support, and, when appropriate, FDA-approved medicines or procedures under clinical supervision.
Questions before anyone “adds a peptide for fat loss”
Ask which paper the forum post means, how long it ran, and whether it used prescription bremelanotide or something else. Ask your clinician which approved obesity options fit your history, and what monitoring those options need. If blood pressure or nausea already limits medicines you take, say so; melanocortin drugs are not gentle on those systems for everyone.
A two-week calorie drop in a supervised research clinic is interesting biology. It is not proof that a research peptide belongs on your bathroom shelf next to a GLP-1 pen.
Not medical advice.
Sources
- Spana C, Jordan R, Fischkoff S. Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials. Diabetes Obes Metab, 2022 (PubMed)
- Full text: Spana et al. 2022 bremelanotide weight trials (PubMed Central)
- DailyMed: Vyleesi (bremelanotide) prescribing information
- NIDDK: Adult overweight and obesity
- MedlinePlus: Obesity
Related reading
- PT-141 research listings do not inherit the Vyleesi file
- What PT-141 studies in men with ED actually found
- Vyleesi desire shots: nausea and blood pressure tradeoffs
By The Everyday Brief. AI-assisted drafting with human editorial review. Sources fetched 2026-10-14 PT. Not medical advice.